# Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea

> **NCT05640232** · PHASE3 · RECRUITING · sponsor: **EMS** · enrollment: 238 (estimated)

## Conditions studied

- Primary Dysmenorrhea

## Interventions

- **DRUG:** CDE100 association
- **DRUG:** Buscopan® Composto association

## Key facts

- **NCT ID:** NCT05640232
- **Lead sponsor:** EMS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-11
- **Primary completion:** 2026-06-28
- **Final completion:** 2027-01-30
- **Target enrollment:** 238 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05640232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05640232, "Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea". Retrieved via AI Analytics 2026-05-19 from https://api.ai-analytics.org/clinical/NCT05640232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*